Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer

Abstract

Background Sputum biopsies offer unique advantages such as non-invasiveness and convenient collection. The one investigation so far on sputum for genome profiling in advanced non-small cell lung cancer (aNSCLC) suggested promising performance. However, it remains undefined whether clinicohistologic characteristics were associated with performance and how this knowledge could help guide choice of liquid biopsy. Methods Targeted sequencing with a 520-gene panel was performed on prospectively collected matched tumor tissue (TIS), plasma (PLA), and sputum supernatant (SPU) from 71 aNSCLC patients (NCT05034445). Genomic alteration detection was characterized in a series of aspects and interrogated for association with 14 clinicohistologic features. Nomograms were constructed with logistic regression for predicting the liquid biopsy type with greater sensitivity. Results Compared with PLA, SPU showed comparable quality control metrics, mutation detection rate (SPU: 67.6%, PLA: 70.4%), concordance with tumor tissue (67.6% vs. 73.2%), and correlation with tissue-based tumor mutation burden levels (r = 0.92 vs. 0.94). For driver alterations, detection was less sensitive with SPU (50.0%) than PLA (63.5%) in the entire cohort but similarly or more sensitive in patients with centrally located lung tumors or smoking history or for altered ALK or KRAS. Two nomograms were constructed and enabled predicting the probability of superior sensitivity with SPU with moderate to borderline high accuracy. Conclusion In addition to demonstrating comparable performance in multiple aspects, this study is the first to propose nomograms for choosing liquid biopsy based on clinicohistologic characteristics. Future research is warranted to delineate the clinical utility of sputum for genome profiling.

Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis

“…Out of 40 eligible papers, 1 was excluded from our meta-analysis ( Xie et al, 2022 ) since only TP and FN were reported in published data. The diagnostic accuracy of cfDNA analysis for the detection of KRAS mutations in NSCLC, compared with tumor tissue was shown in the Forest Plot for 39 studies, including 2,666 NSCLC patients.…”

Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients

“…This study was IRB approved and conducted in accordance with the ethical guidelines including Declaration of Helsinki and US Common Rule. by the Clinical Laboratory Improvement Amendments, according to optimized protocols as described previously (22,23). NGS library construction required a minimum of 30 ng of DNA.…”

“…Sequence data were analyzed using the Burning Rock analysis system as previously described (22,23,26). Briefly, sequence data were mapped to the reference human genome (hg19).…”

Implementação da educação em saúde na prevenção de neoplasias penianas: revisão narrativa

“…Sendo assim, o Câncer de Pulmão de Células Não Pequenas (CPCNP), por ser um dos principais tipos que podem afetar fumantes e não fumantes, está mais relacionado com fatores genéticos, tendo como via comum de todos os cânceres as alterações nuclear e enzimática, dois agentes cruciais para o ciclo celular normal (AIRES; GUEDES, 2018;YIN et al, 2021). complexas e diferentes, sendo assim, a IHQ é capaz de classificar os tipos de neoplasias de modo essencial para o tratamento, prognóstico e recidiva, com auxílio dos marcadores tumorais (INAMURA, 2018;RAJGURU et al, 2020;XIE et al, 2022;YANG et al, 2022).…”